egfr inhibitor lapatinib Search Results


egfr inhibitor lapatinib  (LC Laboratories)
90
LC Laboratories egfr inhibitor lapatinib
Correlation between TP53 and RAS / BRAF V600E mutation expression levels and sensitivity to targeted anticancer agents in pre-clinical models. a Sensitivity to the <t>EGFR</t> inhibitor erlotinib, the MEK inhibitor trametinib, and the MDM2 inhibitor idasanutlin in a panel of 29 unique CRC cell lines plotted according to RAS / BRAF V600E or TP53 mutation status, as indicated (mut, mutated; wt, wild-type; color codes are shown in c ). Higher DSS indicates stronger sensitivity. p -value is from Welch’s t -test of wild-type versus mutated samples. b , c Upper panels show the mutation status for RAS / BRAF V600E and TP53 in each of the 7 selected cell lines and 8 patient-derived organoids (PDOs). Scatter plots show the DSS of matched drugs versus mutant allele expression levels (color-coded as indicated). Spearman’s correlations in blue are for KRAS -mutated PDOs only (excluding the single NRAS -mutated sample). d Scatter plot of RNA-level versus DNA-level MAFs of RAS and TP53 in matched primary and metastatic tumor samples from each of four patients (three with RAS mutations and two with TP53 mutations). Patient 2 showed higher relative expression of the RAS mutant allele in the metastasis
Egfr Inhibitor Lapatinib, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr+inhibitor+lapatinib/her2+egfr+small+molecule+inhibitor+lapatinib+ditosylate/pmc08411524-127-10-19
Average 90 stars, based on 1 article reviews
egfr inhibitor lapatinib - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
dual egfr/her2 inhibitor lapatinib  (RTOG Foundation Inc)
90
RTOG Foundation Inc dual egfr/her2 inhibitor lapatinib
Correlation between TP53 and RAS / BRAF V600E mutation expression levels and sensitivity to targeted anticancer agents in pre-clinical models. a Sensitivity to the <t>EGFR</t> inhibitor erlotinib, the MEK inhibitor trametinib, and the MDM2 inhibitor idasanutlin in a panel of 29 unique CRC cell lines plotted according to RAS / BRAF V600E or TP53 mutation status, as indicated (mut, mutated; wt, wild-type; color codes are shown in c ). Higher DSS indicates stronger sensitivity. p -value is from Welch’s t -test of wild-type versus mutated samples. b , c Upper panels show the mutation status for RAS / BRAF V600E and TP53 in each of the 7 selected cell lines and 8 patient-derived organoids (PDOs). Scatter plots show the DSS of matched drugs versus mutant allele expression levels (color-coded as indicated). Spearman’s correlations in blue are for KRAS -mutated PDOs only (excluding the single NRAS -mutated sample). d Scatter plot of RNA-level versus DNA-level MAFs of RAS and TP53 in matched primary and metastatic tumor samples from each of four patients (three with RAS mutations and two with TP53 mutations). Patient 2 showed higher relative expression of the RAS mutant allele in the metastasis
Dual Egfr/Her2 Inhibitor Lapatinib, supplied by RTOG Foundation Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr+inhibitor+lapatinib/dual+egfr+her2+inhibitor+lapatinib/pmc05813288-143-13-35
Average 90 stars, based on 1 article reviews
dual egfr/her2 inhibitor lapatinib - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Correlation between TP53 and RAS / BRAF V600E mutation expression levels and sensitivity to targeted anticancer agents in pre-clinical models. a Sensitivity to the EGFR inhibitor erlotinib, the MEK inhibitor trametinib, and the MDM2 inhibitor idasanutlin in a panel of 29 unique CRC cell lines plotted according to RAS / BRAF V600E or TP53 mutation status, as indicated (mut, mutated; wt, wild-type; color codes are shown in c ). Higher DSS indicates stronger sensitivity. p -value is from Welch’s t -test of wild-type versus mutated samples. b , c Upper panels show the mutation status for RAS / BRAF V600E and TP53 in each of the 7 selected cell lines and 8 patient-derived organoids (PDOs). Scatter plots show the DSS of matched drugs versus mutant allele expression levels (color-coded as indicated). Spearman’s correlations in blue are for KRAS -mutated PDOs only (excluding the single NRAS -mutated sample). d Scatter plot of RNA-level versus DNA-level MAFs of RAS and TP53 in matched primary and metastatic tumor samples from each of four patients (three with RAS mutations and two with TP53 mutations). Patient 2 showed higher relative expression of the RAS mutant allele in the metastasis

Journal: Genome Medicine

Article Title: The expressed mutational landscape of microsatellite stable colorectal cancers

doi: 10.1186/s13073-021-00955-2

Figure Lengend Snippet: Correlation between TP53 and RAS / BRAF V600E mutation expression levels and sensitivity to targeted anticancer agents in pre-clinical models. a Sensitivity to the EGFR inhibitor erlotinib, the MEK inhibitor trametinib, and the MDM2 inhibitor idasanutlin in a panel of 29 unique CRC cell lines plotted according to RAS / BRAF V600E or TP53 mutation status, as indicated (mut, mutated; wt, wild-type; color codes are shown in c ). Higher DSS indicates stronger sensitivity. p -value is from Welch’s t -test of wild-type versus mutated samples. b , c Upper panels show the mutation status for RAS / BRAF V600E and TP53 in each of the 7 selected cell lines and 8 patient-derived organoids (PDOs). Scatter plots show the DSS of matched drugs versus mutant allele expression levels (color-coded as indicated). Spearman’s correlations in blue are for KRAS -mutated PDOs only (excluding the single NRAS -mutated sample). d Scatter plot of RNA-level versus DNA-level MAFs of RAS and TP53 in matched primary and metastatic tumor samples from each of four patients (three with RAS mutations and two with TP53 mutations). Patient 2 showed higher relative expression of the RAS mutant allele in the metastasis

Article Snippet: The MDM2-TP53 inhibitor idasanutlin (MedChemExpress, Monmouth Junction, NJ, USA), three EGFR inhibitors (afatinib: Selleck Chemicals; erlotinib: MedChemExpress; and lapatinib: LC Laboratories, Woburn, MA, USA) and two MEK inhibitors (binimetinib and trametinib, ChemieTek, Indianapolis, IN, USA) were included in the screens at five and nine different concentrations over a 10,000-fold concentration range each (typically 1–10,000 nmol/L) in the cell lines and PDOs, respectively.

Techniques: Mutagenesis, Expressing, Derivative Assay